X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3309) 3309
Book Review (556) 556
Publication (238) 238
Book Chapter (18) 18
Conference Proceeding (7) 7
Dissertation (5) 5
Reference (2) 2
Data Set (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pioglitazone (2954) 2954
index medicus (2611) 2611
humans (1918) 1918
male (1415) 1415
hypoglycemic agents - therapeutic use (1097) 1097
female (1077) 1077
diabetes mellitus, type 2 - drug therapy (1032) 1032
thiazolidinediones - therapeutic use (1017) 1017
animals (908) 908
rosiglitazone (820) 820
middle aged (818) 818
diabetes (804) 804
thiazolidinediones (782) 782
type 2 diabetes (758) 758
endocrinology & metabolism (735) 735
insulin resistance (634) 634
pharmacology & pharmacy (621) 621
metformin (592) 592
aged (552) 552
thiazolidinediones - pharmacology (551) 551
adult (496) 496
insulin (474) 474
rats (449) 449
diabetes mellitus (434) 434
glucose (421) 421
hypoglycemic agents - pharmacology (404) 404
hypoglycemic agents - adverse effects (403) 403
treatment outcome (397) 397
risk factors (395) 395
mice (385) 385
ppar-gamma (383) 383
insulin-resistance (373) 373
risk (367) 367
thiazolidinediones - adverse effects (344) 344
hypoglycemic agents - administration & dosage (335) 335
drug therapy, combination (317) 317
hypoglycemic agents (317) 317
glycemic control (311) 311
care and treatment (309) 309
diabetes mellitus, type 2 - blood (307) 307
inflammation (307) 307
medicine, general & internal (301) 301
thiazolidinediones - administration & dosage (300) 300
ppar gamma - agonists (281) 281
diabetes mellitus, type 2 - complications (280) 280
mellitus (275) 275
blood glucose - metabolism (273) 273
research (272) 272
drug therapy (270) 270
metformin - therapeutic use (270) 270
analysis (266) 266
expression (266) 266
type-2 diabetes-mellitus (264) 264
obesity (258) 258
double-blind (252) 252
clinical trials (236) 236
abridged index medicus (234) 234
metabolism (229) 229
type 2 diabetes mellitus (223) 223
double-blind method (222) 222
oxidative stress (218) 218
medicine & public health (216) 216
metabolic syndrome (214) 214
troglitazone (213) 213
therapy (212) 212
myocardial-infarction (205) 205
rodents (204) 204
internal medicine (199) 199
diabetes therapy (197) 197
ppar gamma - metabolism (190) 190
blood glucose - drug effects (188) 188
medicine, research & experimental (187) 187
health aspects (184) 184
medicine (184) 184
cardiac & cardiovascular systems (179) 179
randomized controlled-trial (177) 177
mortality (176) 176
research article (172) 172
disease models, animal (168) 168
atherosclerosis (167) 167
thiazolidinedione (167) 167
drugs (165) 165
hyperglycemia (165) 165
studies (165) 165
time factors (165) 165
activated receptor-gamma (162) 162
disease (162) 162
activated-receptor-gamma (157) 157
rats, wistar (154) 154
liver (153) 153
dextrose (152) 152
glycated hemoglobin a - metabolism (152) 152
safety (150) 150
cardiovascular disease (148) 148
efficacy (147) 147
insulin - blood (147) 147
diabetes mellitus, type 2 - metabolism (146) 146
dose-response relationship, drug (146) 146
metaanalysis (145) 145
physiological aspects (145) 145
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3270) 3270
German (14) 14
Spanish (14) 14
French (13) 13
Japanese (7) 7
Korean (4) 4
Italian (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
CIRCULATION-HEART FAILURE, ISSN 1941-3289, 06/2019, Volume 12, Issue 6
Background: Thiazolidinediones (rosiglitazone, pioglitazone) are oral insulin-sensitizing medications used in type 2 diabetes mellitus that reduce glucose with... 
atherosclerosis | heart failure | thiazolidinediones | CARDIAC & CARDIOVASCULAR SYSTEMS | EVENTS | insulin | HEART-FAILURE | diabetes mellitus | DEATH | MELLITUS | PIOGLITAZONE | ROSIGLITAZONE | GLIMEPIRIDE | OUTCOMES | TYPE-2 | Heart failure | Type 2 diabetes | Complications and side effects | Usage | Drug therapy | Thiazolidinediones | Risk factors
Journal Article
Archives of Medical Science, ISSN 1734-1922, 10/2012, Volume 8, Issue 5, pp. 899 - 906
Journal Article
DIABETES CARE, ISSN 0149-5992, 01/2004, Volume 27, Issue 1, pp. 256 - 263
  A consensus statement from the American Heart Association and American Diabetes Association regarding thiazolidinedione use, fluid retention, and congestive... 
INSULIN | TYPE-2 DIABETIC-PATIENTS | RISK-FACTORS | PIOGLITAZONE | MYOCARDIAL-INFARCTION | COMBINATION THERAPY | ENDOCRINOLOGY & METABOLISM | TROGLITAZONE | ROSIGLITAZONE | RECEPTOR-GAMMA AGONIST | FAT DISTRIBUTION | Clinical trials | Cardiovascular disease | Side effects | Diabetes | Drug therapy
Journal Article
Movement Disorders, ISSN 0885-3185, 11/2017, Volume 32, Issue 11, pp. 1594 - 1599
Journal Article
American Heart Journal, ISSN 0002-8703, 2013, Volume 166, Issue 6, pp. 983 - 989.e7
Sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, lowers blood glucose when administered as monotherapy or in combination with other antihyperglycemic... 
Cardiovascular | CARDIAC & CARDIOVASCULAR SYSTEMS | RISK-FACTORS | METAANALYSIS | PIOGLITAZONE | EFFICACY | SAFETY | TOLERABILITY | Metformin - therapeutic use | Humans | Middle Aged | Stroke - complications | Male | Pyrazines - therapeutic use | Cardiovascular Diseases - complications | Thiazolidinediones - therapeutic use | Glycated Hemoglobin A | Aged, 80 and over | Cardiovascular Diseases - blood | Cardiovascular Diseases - mortality | Female | Sitagliptin Phosphate | Drug Therapy, Combination | Diabetes Mellitus, Type 2 - complications | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Double-Blind Method | Sulfonylurea Compounds - therapeutic use | Treatment Outcome | Myocardial Infarction - complications | Diabetes Mellitus, Type 2 - blood | Angina, Unstable - complications | Aged | Diabetes Mellitus, Type 2 - drug therapy | Research Design | Insulin - therapeutic use | Type 2 diabetes | Evaluation | Glucose metabolism | Care and treatment | Blood sugar | Patient outcomes | Clinical trials | Hemoglobin | Hypoglycemic agents | Cardiovascular diseases | Heart attack | Diabetes therapy | Mortality | Cardiovascular disease | FDA approval | Glucose | Abdomen | Ultrasonic imaging | Algorithms | Cysts | Rodents | Insulin resistance | Diabetes | Pancreas | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 08/2017, Volume 46, Issue 4, pp. 470 - 471
Linked ContentThis article is linked to Srinivas paper. To view this article visit https://doi.org/10.1111/apt.14169. 
GASTROENTEROLOGY & HEPATOLOGY | PHARMACOLOGY & PHARMACY | Pioglitazone | Pharmacology | Index Medicus
Journal Article
Psychopharmacology, ISSN 0033-3158, 10/2018, Volume 235, Issue 10, pp. 2957 - 2966
Preliminary evidence suggested that the PPARγ agonist pioglitazone reduces opioid-withdrawal symptoms, possibly by inhibiting increases in proinflammatory... 
Neurosciences | Biomedicine | Buprenorphine | Cytokines | Pioglitazone | Opioid dependence | Pharmacology/Toxicology | Psychiatry | Opioid withdrawal | ACTIVATION | PSYCHIATRY | MORPHINE-WITHDRAWAL | OPIATE WITHDRAWAL | NEUROSCIENCES | DEPENDENCE | REDUCTION | PPAR-GAMMA | PHARMACOLOGY & PHARMACY | CHEMOATTRACTANT PROTEIN-1 | MICE | EXPRESSION | AGONIST | Opioid-Related Disorders - drug therapy | Double-Blind Method | Humans | Middle Aged | Substance Withdrawal Syndrome - drug therapy | Analgesics, Opioid - therapeutic use | Male | Opioid-Related Disorders - blood | Pioglitazone - therapeutic use | Cytokines - cerebrospinal fluid | Buprenorphine - therapeutic use | Narcotic Antagonists - therapeutic use | Opiate Substitution Treatment - methods | Adult | Female | Opioid-Related Disorders - cerebrospinal fluid | Cytokines - blood | Usage | Care and treatment | Patient outcomes | Dosage and administration | Substance abuse | Health aspects | Methods | Urine | Drugs | Drug addiction | Narcotics | Control methods | Clinical trials | Inflammation | Cerebrospinal fluid | Proteins | Monocytes | Randomization | Naloxone | Monocyte chemoattractant protein | Correlation analysis | Opioids | Dependence | Monocyte chemoattractant protein 1 | Heroin | Index Medicus | Clinical Medicine | Neurology | Neurologi | Medical and Health Sciences | Medicin och hälsovetenskap | Pioglitazone; Buprenorphine; Opioid withdrawal; Cytokines; Opioid dependence | Klinisk medicin
Journal Article
Journal Article